MAP2K1 and intrahepatic cholangiocarcinoma: The notion that in ICC cells h-TGF-β1 also acts via MEK/ERK pathway was tested by investigating the effects of MEK1/2 inhibitor U0126 on h-TGF-β1-induced invasiveness of KKU-M213 cells.